Immunomodulating and antiinflammatory agent

Details Immunomodulating and antiinflammatory agent Immunomodulating and antiinflammatory agent

2001-04-23

2003-05-20

Levy, Neil S. (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S002600, C514S004300, C514S008100, C514S399000, C424S278100, C424S810000, C530S387100, C530S868000

Reexamination Certificate

active

06566386

ABSTRACT:

FIELD OF THE INVENTION
The present invention relates to the use of a histamine-added gamma-globulin as pharmaceuticals. More particularly, it relates to an immunomodulating agent, a suppressive agent to hypereosinophilicity and an antiinflammatory agent containing the histamine-added gamma-globulin as an effective component.
BACKGROUND OF THE INVENTION
Histamine-added gamma-globulin restores histamine fixing ability which is lowered in patients suffering from allergy and asthma. It is used as an agent for nonspecific hyposensitizing therapy for bronchial asthma, allergic rhinitis and allergic skin diseases such as urticaria, chronic eczema, atopic dermatitis, etc. Histamine-added gamma-globulin also exhibits suppressive action to liberation of histamine. It does not exhibit side effects exhibited by antihistamines and adrenocortical hormones used as symptomatic remedies. It has therefore been widely used as a pharmaceutical agent with high safety.
The present inventors have found that histamine-added gamma-globulin exhibits unexpected pharmacological action including immunomodulating action, suppressive action towards hypereosinophilicity, and antiinflammatory action.
SUMMARY OF THE INVENTION
The present invention provides pharmaceutical compositions which contain histamine-added gamma-globulin in pharmaceutically effective amounts which are effective as an immunomodulating agent, a hypereosinophilicity suppressive agent, and an antiinflammatory agent. The compositions may be in the form of a liquid injection or a dry preparation which is dissolved upon use for injection. In embodiments of the present invention the compositions may be used for treatment of mammalian diseases associated with an abnormal immune system such as chronic articular rheumatism, systemic lupus erythematosus, multiple sclerosis, and immunodeficiency syndromes. Therapeutic treatment of mammalian infectious diseases, parasitic diseases, respiratory diseases, autoimmune diseases and eosinophilia caused by a malignant tumor may also be achieved with the pharmaceutical compositions. The histamine-added gamma-globulin with about 0.01×10
−3
to about 2×10
−3
parts by weight of a histamine component. In preferred embodiments, from about 5 to about 50 parts by weight gamma-globulin may be combined with about 0.05×10
−3
to about 0.5×10
−3
parts by weight of a histamine component to obtain the histamine-added gamma-globulin.


REFERENCES:
patent: 3873697 (1975-03-01), Filipp et al.
patent: 4704273 (1987-11-01), McMichael
patent: 4705685 (1987-11-01), McMichael
patent: 4705687 (1987-11-01), Lau
patent: 4812449 (1989-03-01), Rideout
patent: 5112738 (1992-05-01), Buckler et al.
patent: 5354848 (1994-10-01), Faligiani et al.
patent: 5622970 (1997-04-01), Armistead et al.
patent: 5639758 (1997-06-01), Sharpe et al.
patent: 5780026 (1998-07-01), Yoshii et al.
patent: 6187803 (2001-02-01), Yoshii et al.
patent: 6238665 (2001-05-01), Naiki
patent: 0 646 376 (1995-04-01), None
patent: 55085526 (1980-06-01), None
Pop, S. et al., “Follow-up of the THG therapeutic action,” Chemical Abstracts Service No. 89-140377 HCA XP002130193. Farmacia (Bucharest) (1978), 26(1), pp. 9-12.
M. Naiki et al., “Neurotropin Inhibits Experimental Allergic Encephalomyelitis (EAE) In Lewis Rats”,Int. J. Immunopharmac., 13(2/3), 235-243 (1991).
“Drug Evaluations Annual 1995”, American Medical Association, pp. 438-445 (1995).
Goodin, “The use of immunosuppressive agents in the treatment of multiple sclerosis: A critical review”,Neurology, vol. 41, pp. 980-985 (1991).
Higashiguchi, et al., Chemical Abstracts 112:111828b, 1990.
Getlik, et al., Chemical Abstracts 67, #5, 20482v, 1967.
Volokhovskaya, et al., Chemical Abstracts, 115:21847q, 1991.
Yoshii, et al., “Inhibitory Effect of Histamine-Added Mouse &ggr;-Globulin On Eosinophil Accumulation Induceb By Allergen In Balb/c Mice”,Japanese Journal of Allergology, 44:567-570 (1995).
Yoshii, et al., “A New Assay System Detecting Antibody Production And Delayed-Type Hypersensitivity Responses To Trinitrophenyl Hapten In An Individual Mouse”,Int. J. Immunopharmac., vol. 18, No. 1, pp. 31-36, 1996.
Fujiwara, et al., “Sandwich enzyme immunoassay of tumor-associated antigen sialosylated Lewis using &bgr;-D-galactosidase coupled to a monoclonal antibody of IgM isotype”,Journal of Immunological Methods, 112, pp. 77-83, 1988.
Burnham, “Polymers for delivering peptides and proteins”,Am J Hosp Pharm, vol. 51, pp. 210-218, Jan. 15, 1994.
Wood, et al., Biochemistry A Problems Approach, 2nd edition, pp. 155-156, 1981.
Naiki, et al., 9th International Congress of Immunology, p. 183, abstract 1084, Jul. 23-29, 1995.
Kaneko, et al., “Role of Interleukin-5 in Local Accumulation of Eosinophils in Mouse Allergic Peritonitis,”Int. Arch Allergy Appl Immunol., 1991; 196: 41-45.
Curtis, et al.,Biology, Fifth edition, Worth Publishers (New York), 1989, pp. 835-836.
Kaplan, A.P.,Allergy, secon dedition, 1977, pp. 148-178, 260-261, 426-427, 439-440, 456-457, 482-483, 554, 597-598, 861-875.
Roitt, I., et al., “Hypersensitivity—Type IV”,Immunology, 2nded., 1989, pp. 22.1-22.10.
Dunn, C.J., et al., “Murine Delayed-Type Hypersensitivity Granuloma: An Improved Model For The Identification And Evaluation Of Different Classes Of Anti-Arthritic Drugs,”Int. J. Immunopharmac., vol. 12, No. 8, p. 899-904, 1990.
Pop, S., et al., “Follow-up of the THG therapeutic action,” Chemical Abstracts Service No. 89-140377 HCA XP002130193. Farmacia (Bucharest) (1978), 26(a), pp. 9-12.
Atton-Chamla et al., “Premenstrual syndrome and atopy: a double-blind clinical evaluation of treatment with a gamma-globulin/histamine complex,”Pharmatherapeuticia, vol. 2, No. 7, 1980, pp. 1025-1029, 1984.
Tanizaki et al., “Inhibitory Effect of Histamine-Gamma Globulin Conjugate on IgE-Mediated Reactivity of Human Basophils,”Jpn. J. Allergol. 33, (12), pp. 1025-1029, 1984.
Peacock, Jr., E.E.,Wound Repair, Third Edition, W.B. Saunders Co., 1984, pp. 96-97.
Fahey et al., “Status of immune-based therapies in HIV infection and AIDS,”Clin. exp. Immunol., 88, 1-5, 1992.
Fundamental Immunology, Third Edition, W.E. Paul, Editor, Raven Press, 1993, pp. 1354-1369.

Affiliated with

Also associated with

Rating

Immunomodulating and antiinflammatory agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Immunomodulating and antiinflammatory agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulating and antiinflammatory agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3047198